Novotech, an international contract research organization (CRO), recently announced the appointment of Dr. Yooni Kim as Executive President, of Asia Pacific (APAC), with effective September 1, 2024.
According to Industry sources, Dr. Yooni Kim brings extensive expertise and leadership experience to her new role with over 25 years of experience in academic research, CROs, and pharmaceutical clinical research. Her leadership is evidenced by the growth of the CRO industry in the Asia Pacific region.
She joined Novotech in 2016 as Executive Director and played a pivotal role in the expansion of business in Asia. In 2019, following Novotech’s merger with PPC, she assumed the role of Vice President of Global Clinical Services, leading Novotech’s global clinical services department and coordinating Novotech’s clinical trial approach with global stakeholders. She holds a Bachelor of Pharmacy degree from Ewha Womans University and a PhD in Preventive Medicine from Seoul National University.
“We are delighted to have Dr. Yooni Kim lead our efforts in the Asia Pacific region,” stated Dr. John Moller, CEO of Novotech. “Her deep understanding of the clinical research landscape in Asia, how it fits into the global clinical research environment, and her leadership skills will be critical as we continue to expand and strengthen our presence in this critical region.”
Dr. Moller added: “Asia Pacific is a key market for Novitech’s business, so this appointment will bring a highly experienced, client-focused leader to the region who will oversee all aspects of operations and management to deliver reliable, achievable outcomes for our clients’ clinical trial programs.”
Industry sources added that in her new role as Executive President, of Asia Pacific, Dr. Yooni Kim will be responsible for the Asia Pacific region for NovoTech, providing strategic direction to the teams and ensuring the smooth operation of the business in the region.
Dr. Yooni Kim stated, “I am very excited to take on this role. I will take strategic initiatives to enhance NovoTech’ capabilities in the Asia Pacific region. I will work in an organized manner, prioritize customer needs, and strive to ensure that we provide customers with value that exceeds their expectations and excellent service. I will also continue to maintain close contact with key opinion leaders (KOLs) and regulatory agencies, and strengthen partnerships with clinical trial institutions in the region. I believe this will help leverage the region’s strong capabilities for the benefit of our customers’ clinical trial programs.”
Industry sources further confirmed that NovoTech positions itself as an international professional CRO for all phases of clinical trials. This strategic appointment is an important manifestation of its commitment to expanding its global business scope and strengthening its operational capabilities. NovoTech has now developed into an international enterprise organization, and for this reason, we reiterate our commitment to maintaining a global pace of development and a regional proactive response.
Industry sources also added that the establishment of the Executive President of Asia Pacific is a pivotal initiative in achieving this commitment and will also help Novartis align its business in major regions such as the United States, Europe, Mainland China, and Asia Pacific. Dr. Kim will also join the NovoTech Executive Committee and make valuable contributions to the company’s strategic direction and global initiatives.
